Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2019 / N 2

Генетические факторы механизмов формирования когнитивных нарушений у пациентов с сахарным диабетом на основании анализа GWAS
М.В. Матвеева, Ю.Г. Самойлова, Н.Г. Жукова

Список литературы

1. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004 Nov;292(18):2237-42.
2. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Archives of Neurology 2007 Apr;64(4):570-5.
3. Ravaglia G, Forti P, Montesi F, Lucicesare A, Pisacane N, Rietti E, Dalmonte E, Bianchin M, Mecocci P. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. Journal of the American Geriatrics Society 2008 Jan;56(1):51-8.
4. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia and Geriatric Cognitive Disorders 2002;14(2):77-83.
5. Xu W, Caracciolo B, Wang HX, Winblad B, Bäckman L, Qiu C, Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010 Nov;59(11):2928-35.
6. Аметов А.С., Камынина Л.Л., Ахмедова З.Г. Клинические аспекты генетики, нутриогенетики и фармакогенетики сахарного диабета 2-го типа. Терапевтический архив 2015;87(8):124-31.
7. Yuan XY, Wang XG. Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. Reviews in the Neurosciences 2017 Oct;28(7):715-23.
8. Дедов И.И., Смирнова О.М., Кононенко И.В. Значение результатов полногеномных исследований для первичной профилактики сахарного диабета 2 типа и его осложнений. Персонализированный подход. Сахарный диабет 2014;(2):10-9.
9. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, McClearn G. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. International Psychogeriatrics 2002 Sep;14(3):239-48.
10. Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bottiglieri T. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 2005 Nov;65(9):1402-8.
11. Manschot SM, Biessels GJ, de Valk H, Algra A, Rutten GE, van der Grond J, Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007 Nov;50(11):2388-97.
12. Yao XH, Shen K, Li XJ. Effects of insulin on the diseases of central nervous system. Sheng Li Ke Xue Jin Zhan 2003 Jan;34(1):21-6.
13. Frölich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer’s disease. Annals of the New York Academy of Sciences 1999;893:290-3.
14. Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, Craft S. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006 May 23;66(10):1506-10.
15. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. The American Journal of Pathology 2004 Apr;164(4):1425-34.
16. Varghese A, Asha NS, Celine TM, Prasanna D. Inflammatory markers in type II diabetes mellitus. The Pharma Innovation Journal 2015;4(7):64-6.
17. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Current Drug Targets CNS and Neurological Disorders 2005 Jun;4(3):249-66.
18. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. The Journal of Immunology (Baltimore, Md.: 1950) 2009 May;182(9):5778-88.
19. Clark KL, Noudoost B. The role of prefrontal catecholamines in attention and working memory. Frontiers in Neural Circuits 2014 Apr;8:33.
20. Bertoldi M. Mammalian dopa decarboxylase: structure, catalytic activity and inhibition. Archives of Biochemistry and Biophysics 2014 Mar;546:1-7.
21. Martelle SE, Raffield LM, Palmer ND, Cox AJ, Freedman BI, Hugenschmidt CT, Williamson JD, Bowden DW. Dopamine pathway gene variants may modulate cognitive performance in the DHS-Mind Study. Brain and Behavior 2016 Mar;6(4):e00446.
22. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer’s disease. Current Pharmaceutical Design 2008;14(16):1601-5.
23. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer’s disease. Journal of Alzheimer’s Disease 2011;24(1):25-34.
24. Smith CE, Tucker KL, Scott TM, Rompay MV, MatteiJ, Lai CQ, Parnell LD, Junyent M, Lee YC, Garcia-Bailo B, Ordovás JM. Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One 2009;4(5):e5465.
25. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Archives of Neurology 2004 Dec;61(12):1930-4.
26. Suganami T, Yuan X, Shimoda Y, Uchio-Yamada K, Nakagawa N, Shirakawa I, Usami T, Tsukahara T, Nakayama K, Miyamoto Y, Yasuda K, Matsuda J, Kamei Y, Kitajima S, Ogawa Y. Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue. Circulation Research 2009 Jul;105(1):25-32.
27. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Subcellular Biochemistry 2012;65:329-52.
28. Jiménez-Palomares M, Ramos-Rodríguez JJ, López-Acosta JF, Pacheco-Herrero M, Lechuga-Sancho AM, Perdomo G, García-Alloza M, Cózar-Castellano I. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism 2012 Jun;302(11):E1373-80.
29. Cummings JL. Treatment of Alzheimer’s disease: current and future therapeutic approaches. Reviews in Neurological Diseases 2004 Spring;1(2):60-9.
30. Sima AAF, Zhang W, Xu G, Sugimoto K, Guberski D, Yorek MA. A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor-rat and in type I diabetic BB/Wor-rat. Diabetologia 2000 Jun;43(6):786-93.
31. Wang XF, Lin X, Li DY, Zhou R, Greenbaum J, Chen YC, Zeng CP, Peng LP, Wu KH, Ao ZX, Lu JM, Guo YF, Shen J, Deng HW. Linking Alzheimer’s disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach. Journal of Neurological Sciences 2017 Sep;380:262-72.
32. Luciano M, Mõttus R, Harris SE, Davies G, Payton A, Ollier WER, Horan MA, Starr JM, Porteous DJ, Pendleton N, Deary IJ. Predicting cognitive ability in ageing cohorts using Type 2 diabetes genetic risk. Diabetic Medicine 2014 Jun;31(6):714-20.

References

1. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004 Nov;292(18):2237-42.
2. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Archives of Neurology 2007 Apr;64(4):570-5.
3. Ravaglia G, Forti P, Montesi F, Lucicesare A, Pisacane N, Rietti E, Dalmonte E, Bianchin M, Mecocci P. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. Journal of the American Geriatrics Society 2008 Jan;56(1):51-8.
4. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia and Geriatric Cognitive Disorders 2002;14(2):77-83.
5. Xu W, Caracciolo B, Wang HX, Winblad B, Bäckman L, Qiu C, Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010 Nov;59(11):2928-35.
6. Ametov AS, Kamynina LL, Akhmedova ZG. Type 2 diabetes mellitus: clinical aspects of genetics, nutrigenetics and pharmacogenetics. Therapeutic Archive 2015;87(8):124-31 (In Russian).
7. Yuan XY, Wang XG. Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. Reviews in the Neurosciences 2017 Oct;28(7):715-23.
8. Dedov II, Smirnova OM, Kononenko IV. Significance of genome-wide study results for primary prevention of type 2 diabetes and its complications. Personalized approach. Diabetes Mellitus 2014;(2):10-9 (In Russian).
9. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, McClearn G. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. International Psychogeriatrics 2002 Sep;14(3):239-48.
10. Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bottiglieri T. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 2005 Nov;65(9):1402-8.
11. Manschot SM, Biessels GJ, de Valk H, Algra A, Rutten GE, van der Grond J, Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007 Nov;50(11):2388-97.
12. Yao XH, Shen K, Li XJ. Effects of insulin on the diseases of central nervous system. Sheng Li Ke Xue Jin Zhan 2003 Jan;34(1):21-6.
13. Frölich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer’s disease. Annals of the New York Academy of Sciences 1999;893:290-3.
14. Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, Craft S. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006 May 23;66(10):1506-10.
15. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. The American Journal of Pathology 2004 Apr;164(4):1425-34.
16. Varghese A, Asha NS, Celine TM, Prasanna D. Inflammatory markers in type II diabetes mellitus. The Pharma Innovation Journal 2015;4(7):64-6.
17. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Current Drug Targets CNS and Neurological Disorders 2005 Jun;4(3):249-66.
18. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. The Journal of Immunology (Baltimore, Md.: 1950) 2009 May;182(9):5778-88.
19. Clark KL, Noudoost B. The role of prefrontal catecholamines in attention and working memory. Frontiers in Neural Circuits 2014 Apr;8:33.
20. Bertoldi M. Mammalian dopa decarboxylase: structure, catalytic activity and inhibition. Archives of Biochemistry and Biophysics 2014 Mar;546:1-7.
21. Martelle SE, Raffield LM, Palmer ND, Cox AJ, Freedman BI, Hugenschmidt CT, Williamson JD, Bowden DW. Dopamine pathway gene variants may modulate cognitive performance in the DHS-Mind Study. Brain and Behavior 2016 Mar;6(4):e00446.
22. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer’s disease. Current Pharmaceutical Design 2008;14(16):1601-5.
23. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer’s disease. Journal of Alzheimer’s Disease 2011;24(1):25-34.
24. Smith CE, Tucker KL, Scott TM, Rompay MV, MatteiJ, Lai CQ, Parnell LD, Junyent M, Lee YC, Garcia-Bailo B, Ordovás JM. Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One 2009;4(5):e5465.
25. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Archives of Neurology 2004 Dec;61(12):1930-4.
26. Suganami T, Yuan X, Shimoda Y, Uchio-Yamada K, Nakagawa N, Shirakawa I, Usami T, Tsukahara T, Nakayama K, Miyamoto Y, Yasuda K, Matsuda J, Kamei Y, Kitajima S, Ogawa Y. Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue. Circulation Research 2009 Jul;105(1):25-32.
27. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Subcellular Biochemistry 2012;65:329-52.
28. Jiménez-Palomares M, Ramos-Rodríguez JJ, López-Acosta JF, Pacheco-Herrero M, Lechuga-Sancho AM, Perdomo G, García-Alloza M, Cózar-Castellano I. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism 2012 Jun;302(11):E1373-80.
29. Cummings JL. Treatment of Alzheimer’s disease: current and future therapeutic approaches. Reviews in Neurological Diseases 2004 Spring;1(2):60-9.
30. Sima AAF, Zhang W, Xu G, Sugimoto K, Guberski D, Yorek MA. A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor-rat and in type I diabetic BB/Wor-rat. Diabetologia 2000 Jun;43(6):786-93.
31. Wang XF, Lin X, Li DY, Zhou R, Greenbaum J, Chen YC, Zeng CP, Peng LP, Wu KH, Ao ZX, Lu JM, Guo YF, Shen J, Deng HW. Linking Alzheimer’s disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach. Journal of Neurological Sciences 2017 Sep;380:262-72.
32. Luciano M, Mõttus R, Harris SE, Davies G, Payton A, Ollier WER, Horan MA, Starr JM, Porteous DJ, Pendleton N, Deary IJ. Predicting cognitive ability in ageing cohorts using Type 2 diabetes genetic risk. Diabetic Medicine 2014 Jun;31(6):714-20.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]